In preclinical studies, PLD inhibitors [FIPI (dual PLD1/PLD2 inhibitor) or VU0155072-2 (PLD2 inhibitor)] were found to reduce the tumor-promoting macrophages and neutrophil infiltration in primary breast tumors and liver metastasis, thereby suppressing BCLM (86). Here, PLD2 is linked to breast neoplasm.